SCHEMBL4067731

SCHEMBL4067731

c1ccc(-c2cc3ncnc(NCc4cccs4)c3s2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 4/20 0.57
CLK4 Q9HAZ1 10/20 0.56
NPC1 O15118 1/20 0.54
DYRK1A Q13627 4/20 0.54
LMNA P02545 6/20 0.53
CYP1A2 P05177 5/20 0.53
CYP3A4 P08684 5/20 0.53
CYP2D6 P10635 5/20 0.53
CYP2C19 P33261 5/20 0.53
ALDH1A1 P00352 4/20 0.53
CYP2C9 P11712 4/20 0.53
MAPK1 P28482 4/20 0.53
HIF1A Q16665 4/20 0.53
TSHR P16473 3/20 0.53
HSD17B10 Q99714 3/20 0.53
USP2 O75604 3/20 0.53
RECQL P46063 2/20 0.53
MAPT P10636 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930448 0.89 FLT1 (0.56) FLT1CLK4NPC1LMNAALDH1A1
SCHEMBL3936767 0.81 NPR1 (0.61) FLT1CLK4NPC1LMNACYP1A2
SCHEMBL4070015 0.81 SMN1; SMN2 (0.57) FLT1CLK4DYRK1ALMNACYP1A2
SCHEMBL4071062 0.80 TYK2 (0.62) FLT1NPC1LMNAMAPTTP53
SCHEMBL4066184 0.80 FLT1 (0.56) FLT1NPC1ALDH1A1KDM4ETP53
SCHEMBL4067658 0.79 FLT1 (0.61) FLT1NPC1LMNAALDH1A1MAPK1
SCHEMBL24466947 0.78 NPR1 (0.66) FLT1CLK4LMNACYP1A2CYP3A4
SCHEMBL4069915 0.78 EGFR (0.72) FLT1CLK4LMNACYP1A2CYP3A4
SCHEMBL4071128 0.77 EGFR (0.62) FLT1CLK4LMNACYP1A2CYP3A4
SCHEMBL3932470 0.77 EGFR (0.59) FLT1CLK4NPC1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 FLT1 3521/4885CLK4 4484/4885NPC1 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.